Day: September 21, 2022

DELTA, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) — WestBond Enterprises Corporation (TSX-V: WBE) is pleased to report that all matters were approved at the Company’s Annual General shareholders meeting (the “Meeting”) held on August 31, 2022. At the Meeting the Company’s shareholders re-elected all of the Company’s current board of directors, Gennaro Magistrale, J. Douglas Seppala, D. Dan Dawson and Peter R. Toigo as well as approved the re-appointment of the Company’s current auditor, PricewaterhouseCoopers LLP. The Company’s shareholders also approved the adoption of a new 10% rolling stock option plan in accordance with the requirements of the TSX Venture Exchange. For further information please contact: Gennaro Magistrale Chief Executive Officer, President and DirectorWestBond Enterprises Corporation101 – 7403 Progress...

CALGARY, Alberta, Sept. 21, 2022 (GLOBE NEWSWIRE) — Maxim Power Corp. (“MAXIM” or the “Corporation”) (TSX: MXG) provides updates on its 204 MW Milner 2 (“M2”) operations and the Combined Cycle Gas Turbine (“CCGT”) expansion of M2 project. M2 OPERATIONS AND CCGT PROJECT UPDATES As previously reported, M2 commenced cold commissioning activities related to the CCGT expansion project in the third quarter of 2022. These activities include taking the M2 gas turbine offline to allow for the connection of the heat recovery steam generator, steam turbine and related components. As a result of these activities, the M2 facility has been offline since early September. MAXIM anticipates that the CCGT expansion of M2 will begin hot commissioning activities early in the fourth quarter of 2022, which will result in intermittent...

OAKLAND, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) — Today, Vice President Kamala Harris and US Treasury Secretary Janet L. Yellen announced that the US Treasury Department completed $671 million in preferred stock investments in ten Community Development Financial Institutions (“CDFI”) or Minority Depository Institutions (“MDI”) headquartered in California under the Emergency Capital Investment Program (“ECIP”). Bay Community Bancorp, (OTC Pink: CBOBA) (the “Company”), previously announced that its wholly-owned subsidiary, Community Bank of the Bay, (the “Bank”) a San Francisco Bay Area commercial bank and California’s first FDIC insured CDFI with full-service offices in Oakland, Danville and San Mateo, completed a $119.4 million investment from the US Treasury Department on June 7, 2022. The Company’s $119.4 million investment...

MONACO, Sept. 21, 2022 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”) announced today that it has purchased its common shares in the open market and exercised a purchase option for an LR2 product tanker that is currently leased. Purchase of Common Shares The Company purchased 137,459 of its common shares in the open market at an average price of $43.27 per share as part of the Company’s securities repurchase program. The Company has $169.1 million remaining under its securities repurchase program as of the date of this press release. The acquired common shares are being held as treasury shares. The Company expects to repurchase any securities in the open market, at times and prices that are considered to be appropriate by the Company, but is not obligated under the terms of the program...

Montrouge, France, September 21, 2022 DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) in the form of a partial clinical hold on its VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy) Phase 3 clinical study. In the partial clinical hold letter, the FDA specifies changes to elements of the VITESSE protocol with the intent for the trial to support a future BLA submission. Within the FDA’s communication, the modifications address design elements, including the statistical analysis of adhesion, minimum daily wear time and technical alignments in methods of categorizing data,...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022. The Company’s webcast presentation will be available for viewing at 9:00am ET on Wednesday, September 28, 2022, on the Company’s website at Events & Presentations or https://investors.mannkindcorp.com/events-and-presentations. The webcast will also be archived and available for replay. Management will be participating in virtual one-on-one meetings throughout the event....

VANCOUVER, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) — Methanex Corporation (the “Company” or “Methanex”) (TSX:MX) (NASDAQ:MEOH) announced today that the Toronto Stock Exchange (the “TSX”) has approved the Company’s previously announced Normal Course Issuer Bid (“NCIB”). Pursuant to the NCIB, the Company will purchase for cancellation up to 3,506,405 common shares (“Shares”), representing 5% of the 70,128,109 Shares issued and outstanding as of September 15, 2022. Purchases will be made on the open market through the facilities of the TSX and will commence on September 26, 2022 and end no later than September 25, 2023. Any purchases will be made from time to time at the then current market price of the Shares and all Shares purchased under the NCIB will be cancelled. Subject to certain exceptions for block purchases,...

Publication includes the Phase 3 VALOR SOD1-ALS trial and its open-label-extension study, underscoring the importance of these longer-term data 12-month data show earlier initiation of tofersen slowed decline across critical measures of function and strength in people diagnosed with SOD1-ALS Results offer important learnings regarding the biology of SOD1-ALS and design of ALS clinical trialsCAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that The New England Journal of Medicine (NEJM) has published detailed results from the Phase 3 VALOR study and the combined analysis of VALOR and its open label extension (OLE) study evaluating tofersen for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). There is currently no treatment targeted for SOD1-ALS. “I...